Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $38.06 USD
Change Today -3.73 / -8.93%
Volume 5.3M
SRPT On Other Exchanges
As of 3:00 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

sarepta therapeutics inc (SRPT) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/5/15 - $41.97
52 Week Low
01/14/15 - $11.33
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

sarepta therapeutics inc (SRPT) Details

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin. The company also focuses on developing therapeutics for the treatment of drug-resistant bacteria, Becker muscular dystrophy, progeria, adult onset pompe, lupus and graft-versus-host diseases; and other rare, genetic, anti-infective, neuromuscular, and central nervous system diseases. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

204 Employees
Last Reported Date: 02/26/15
Founded in 1980

sarepta therapeutics inc (SRPT) Top Compensated Officers

Interim Chief Executive Officer, Chief Medica...
Total Annual Compensation: $399.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $443.7K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $393.4K
Senior Vice President of Technical Operations
Total Annual Compensation: $335.9K
Compensation as of Fiscal Year 2014.

sarepta therapeutics inc (SRPT) Key Developments

Sarepta Therapeutics Announces Collaborative Research Agreement with Murdoch University Researchers Steve Wilton and Sue Fletcher

Sarepta Therapeutics announced a four year collaborative research agreement to establish the Sarepta Translational Laboratory with Murdoch University, Perth, Western Australia. The Laboratory, led by Murdoch University professors Steve Wilton, Ph.D. and Sue Fletcher, Ph.D., will explore the applicability of the Company's phosphorodiamidate morpholino oligomer (PMO) technology for disease targets beyond Duchenne muscular dystrophy (DMD), such as cystic fibrosis and spinal muscular atrophy. The agreement provides the Murdoch University researchers with access to Sarepta's PMO platform technology, as well as additional funding for researchers and materials. The initial project for the collaboration is anticipated to target multiple sclerosis. As part of the collaborative agreement, Sarepta will have exclusive rights to license technology and/or products resulting from the research projects.

Sarepta Therapeutics, Inc. Announces Additional Long-Term Efficacy and Safety Data from Pivotal Phase IIb Program of Eteplirsen for Treatment of Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc. announced additional clinical efficacy and safety data from the company’s Phase IIb program of eteplirsen in patients with Duchenne muscular dystrophy (DMD). The data demonstrated that eteplirsen provided a statistically significant advantage of 151 meters in the ability of study participants to walk at three years, compared with external controls. Further, the fourth biopsy data confirmed the mechanism of action of eteplirsen, demonstrating exon skipping in all patients and dystrophin production in nearly all patients. Safety data remained consistent with prior results. Eteplirsen, Sarepta’s lead drug candidate, is designed to target the underlying cause of DMD by enabling the production of a functional dystrophin protein in patients with mutations amenable to exon 51 skipping. Approximately 13% of people with DMD are estimated to have a mutation targeted by eteplirsen/exon 51 skipping. Results of Sarepta’s Phase IIb program were included in the New Drug Application (NDA) that Sarepta submitted to the U.S. Food and Drug Administration (FDA) for eteplirsen for the treatment of DMD amenable to exon 51 skipping. The primary clinical endpoint in the NDA was the comparison of the 6MWT ITT analysis of the eteplirsen-treated group compared to an external control with similar inclusion criteria. The FDA granted eteplirsen Priority Review status and assigned a Prescription Drug User Fee Act (PDUFA) action date of February 26, 2016. Previously, the FDA granted Rare Pediatric Disease Designation to eteplirsen, as well Orphan Drug Designation and Fast Track Status. New results from a fourth biopsy performed on 11 patients demonstrated that exon skipping occurred in 100% of patients after 180 weeks of treatment, confirming the mechanism of action of eteplirsen. In addition, biochemical evidence from three quantification methods, analysis of dystrophin positive fibers, dystrophin intensity and Western Blot testing, confirmed that dystrophin was present in most patients following eteplirsen treatment.

Sarepta Therapeutics, Inc. Appoints Jean-Paul Kress to its Board of Directors

Sarepta Therapeutics, Inc. announced the appointment of Jean-Paul Kress, M.D., to the company’s board of directors. Jean-Paul Kress, M.D., is the recently appointed Head of North America, Sanofi Genzyme Specialty Care Business Unit (Multiple Sclerosis, Oncology & Immunology). Prior to this appointment, Jean-Paul served as the President and CEO of Sanofi Pasteur MSD, the leading European vaccine company.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRPT:US $38.06 USD -3.73

SRPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arbutus Biopharma Corp $6.07 USD -0.23
Dicerna Pharmaceuticals Inc $8.28 USD -0.60
Galena Biopharma Inc $1.74 USD -0.035
Regulus Therapeutics Inc $6.50 USD -0.05
Silence Therapeutics PLC 224.25 GBp -5.75
View Industry Companies

Industry Analysis


Industry Average

Valuation SRPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,591.4x
Price/Book 10.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,429.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at